1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Rheumatoid Arthritis Therapeutics in South-East Asia Markets to 2022 - Novel JAK and IL-6 Receptor Inhibitors to Stimulate Moderate Growth Despite Launch of Biosimilars of Blockbuster Anti-TNFs

Rheumatoid Arthritis Therapeutics in South-East Asia Markets to 2022 - Novel JAK and IL-6 Receptor Inhibitors to Stimulate Moderate Growth Despite Launch of Biosimilars of Blockbuster Anti-TNFs

  • April 2017
  • ID: 4883823

Summary

Table of Contents

Search Inside

Rheumatoid Arthritis Therapeutics in South-East Asia Markets to 2022 - Novel JAK and IL-6 Receptor Inhibitors to Stimulate Moderate Growth Despite Launch of Biosimilars of Blockbuster Anti-TNFs

Summary

Rheumatoid arthritis (RA) is a chronic, progressive and currently incurable autoimmune disease that primarily affects the joints. It is characterized by synovial inflammation and gradual bone erosion over many years (Lefèvre et al., 2009). Disease progression results in stiffness and pain, especially in the hands and feet, which hinders mobility. Without treatment, the disease leads to joint destruction and disability. RA can have a substantial impact on quality of life and place a considerable economic burden upon the patient.

The advent of biologic disease-modifying anti-rheumatic drugs (DMARD) has boosted the rheumatoid arthritis (RA) market tremendously over the last two decades. The South-East Asia market, which for the purposes of this report comprises South Korea, Singapore, Taiwan, Malaysia, the Philippines, Thailand, Vietnam, and Indonesia, is forecast to grow at a compound annual growth rate (CAGR) of 4.7%, from USD1.04 Billion in 2015 to USD1.44 Billion in 2022. South Korea accounted for most of the market in 2015 with a 29.9% share, followed by Malaysia with 19.0%, the Philippines with 14.2%, Vietnam with 9.4%, Taiwan with 8.5%, Indonesia with 7.1%, Singapore with 6.4%, and Thailand with 5.5%.

The entry of new therapies over the forecast period will stimulate market growth. Promising pipeline candidates include Eli Lilly and Incyte’s baricitinib, Regeneron’s sarilumab, GlaxoSmithKline (GSK) and Johnson & Johnson’s sirukumab, Astellas’ peficitinib (ASP015K), and AbbVie’s upadacitinib. Galapagos’ filgotinib is in late-stage development, but it will not be launched during the forecast period, as its Phase III trial completion date is in Q3 2020.

The therapeutic market for RA has become extremely competitive owing to the number of new drug approvals. Competition for tumor necrosis factor alpha (TNF-?) inhibitors is particularly fierce and now dominates the treatment market for RA patients who are refractory to first-line DMARDs. In 2015, Humira (adalimumab), MabThera/Rituxan (rituximab) and Remicade (infliximab) were ranked among the top-10 best-selling drugs in the world, with global revenue of USD14.01 Billion, USD7.33 Billion and USD6.56 Billion, respectively, reflecting their groundbreaking clinical and commercial success.

The report "Rheumatoid Arthritis Therapeutics in South-East Asia Markets to 2022 - Novel JAK and IL-6 Receptor Inhibitors to Stimulate Moderate Growth Despite Launch of Biosimilars of Blockbuster Anti-TNFs" provides an introduction to rheumatoid arthritis (RA), covering epidemiology, symptoms, etiology and pathophysiology, diagnosis, prognosis, treatment guidelines and options, and co-morbidities and complications. Disease classification and methods of diagnosis are also provided.

In addition, this report also provides the following analysis -
- Provides an overview of the RA marketed products landscape, including product profiles of key marketed products and heat maps that compare the safety and efficacy parameters of the various drugs.
- Analyzes the RA pipeline, detailing, among other parameters, drug distribution by stage of development, molecule type and molecular target. The chapter concludes with an analysis of promising pipeline molecules, including product profiles and a heatmap that compares the efficacy and safety data for the various drugs.
- Provides detailed analysis of recent clinical trials in RA by enrollment, duration and failure rate. Finally, promising late-stage pipeline molecules are analyzed and assessed in terms of their potential competitive strength.
- Supplies forecasts for the RA market, including epidemiology, treatment usage patterns, pricing, and market size, for the 2015–2022 period. The eight South-East Asia markets are covered and data are presented at a country level.
- Provides detailed analysis of key market drivers and barriers for RA in South-East Asia markets.

Companies mentioned in this report: Eli Lilly and Incyte’s baricitinib, Regeneron’s sarilumab, GlaxoSmithKline (GSK) and Johnson & Johnson’s sirukumab, Astellas’ peficitinib (ASP015K), and AbbVie’s upadacitinib. Galapagos’ filgotinib

Scope

The current South-East Asia RA market contains novel products, including Xeljanz, a JAK inhibitor; and Actemra (tocilizumab), an IL-6 receptor inhibitor.
- What are the competitive advantages of the existing novel drugs?
There are over 450 active pipeline molecules, and most of the late-stage investigational drug candidates feature improved dosing regimens and administration routes in comparison to currently marketed products and combination therapies.
- Which classes of novel drugs are most prominent in the pipeline?
- What is the potential for pipeline products to address unmet needs in the RA market?
Analysis of clinical trials since 2006 identified that the failure rates of RA molecules were highest in Phase II, at 72.6%, with the overall attrition rate for RA standing at 94.6%.
- How do failure rates vary by stage of development, molecule type, and molecular target?
- How do other factors, such as average trial duration and trial size, influence the costs and risks associated with product development?
Over the 2015-2022 forecast period, the South-East Asia RA therapeutics market is expected to increase in value at a CAGR of 4.7%, from $1.04 billion to over $1.4 billion.
- Which markets make the most significant contribution to the current market size?
- What are the epidemiology trends in these markets?
- Will new market entrants lead to substantial changes in annual therapy costs?
- How will different treatment usage patterns impact growth in the eight assessed South-East Asia markets?
Rising RA prevalence population and the uptake of newer therapies will lead to significant market growth over the forecast period, despite the launch of biosimilars of blockbuster anti-TNFs.
- Will the launch of biosimilars or emerging pipeline molecules threaten the commercial success of existing drugs?

Reasons to buy

This report will enable you to -
- Understand the clinical context of RA by considering epidemiology, symptoms, etiology and pathophysiology, diagnosis, prognosis and treatment guidelines and options.
- Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need.
- Identify key pipeline trends in terms of molecule type, administration route, molecular target, and novelty.
- Consider market opportunities and potential risks by examining trends in RA clinical trial size, duration, and failure rate by stage of development, molecule type, and molecular target.
- Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in RA by examining clinical trial data and multi-scenario product forecast projections.
- Compare treatment usage patterns, annual therapy costs, and market growth projections for South Korea, Singapore, Taiwan, Malaysia, the Philippines, Thailand, Vietnam, and Indonesia.
- Discover trends in licensing and co-development deals concerning RA products and identify the major strategic consolidations that have shaped the commercial landscape.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Cytomegalovirus (CMV): Opportunity Analysis and Forecasts to 2027

Cytomegalovirus (CMV): Opportunity Analysis and Forecasts to 2027

  • $ 10995
  • Industry report
  • June 2018
  • by GlobalData

Cytomegalovirus (CMV): Opportunity Analysis and Forecasts to 2027SummaryFor nearly two decades, the Cytomegalovirus (CMV) therapeutics landscape has been dominated by ganciclovir and valganciclovir, with ...

Peanut Allergy: Opportunity Analysis and Forecasts to 2027

Peanut Allergy: Opportunity Analysis and Forecasts to 2027

  • $ 10995
  • Industry report
  • June 2018
  • by GlobalData

Peanut Allergy: Opportunity Analysis and Forecasts to 2027SummaryGlobal Peanut Allergy marketplace (8 major pharmaceutical markets - US, France, Germany, Italy, Spain, UK, Canada, and Australia) is to ...

Ulcerative Colitis: Global Drug Forecast and Market Analysis to 2026

Ulcerative Colitis: Global Drug Forecast and Market Analysis to 2026

  • $ 10995
  • Industry report
  • June 2018
  • by GlobalData

Ulcerative Colitis: Global Drug Forecast and Market Analysis to 2026SummaryThe current Ulcerative Colitis (UC) market is overcrowded with cheap generic drugs for mild to moderate disease, as well as expensive ...

Biosimilars in Oncology $ 7995 August 2018


ref:plp2017

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on